Volume 4, Issue 1 (2019)
SJMR 2019, 4(1): 71-75 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mosadegh H. Properties and Maternal and Fetal Complications in Pre-eclampsia Patients, Case Study of Sarem Women’s Hospital. SJMR 2019; 4 (1) :71-75
URL: http://saremjrm.com/article-1-122-en.html
URL: http://saremjrm.com/article-1-122-en.html
Sarem Fertility and Infertility Research Center, Sarem Women’s Hospital, Tehran, Iran , dr.mosadegh.homeira@gmail.com
Abstract: (4200 Views)
Aims: Pre-eclampsia is one of the major cause of maternal mortality and morbidity. The aim of this study was to investigate epidemiological and fetal and maternal complications in preeclamptic patients.
Materials & Methods: The files of 195 patients with pre-eclampsia who were admitted to the Sarem hospital from 2010 to 2015 were investigated and information was recorded in the pre-prepared checklist.
Findings: Of the total patients, 63.9% were asymptomatic, such as loss of consciousness, epigastric pain, headache and seizure. There was no case of maternal death and only one case of intrauterine fetal death (IUFD) was available in the records. Maternal complications were observed in patients. Fetal complications were observed in 26.2% of patients. Antiphospholipid syndrome was observed in 3.1% of patients with maternal complications compared to 1% of uncomplicated mothers (p=0.001). Serum glutamic-oxaloacetic transaminase (SGOT) mean was 49.5 in mothers with complications and 26.94 in mothers without complications (p=0.043). Serum glutamic-pyruvic transaminase (SGPT) mean was 60.13 in mothers with complications compared to 23.87 in uncomplicated mothers (p=0.001). Lactate dehydrogenase (LDH) mean was 2235.38 in mothers with complications and 735.02 in mothers without complications. In patients with fetal complications LDH levels were 385.35 and in cases without fetal complications 375.02.
Conclusion: The level of liver enzymes and the presence of antiphospholipid syndrome are considered as predictors of maternal complications, while lactate dehydrogenase and signaling in the mother predict maternal and fetal complications.
Materials & Methods: The files of 195 patients with pre-eclampsia who were admitted to the Sarem hospital from 2010 to 2015 were investigated and information was recorded in the pre-prepared checklist.
Findings: Of the total patients, 63.9% were asymptomatic, such as loss of consciousness, epigastric pain, headache and seizure. There was no case of maternal death and only one case of intrauterine fetal death (IUFD) was available in the records. Maternal complications were observed in patients. Fetal complications were observed in 26.2% of patients. Antiphospholipid syndrome was observed in 3.1% of patients with maternal complications compared to 1% of uncomplicated mothers (p=0.001). Serum glutamic-oxaloacetic transaminase (SGOT) mean was 49.5 in mothers with complications and 26.94 in mothers without complications (p=0.043). Serum glutamic-pyruvic transaminase (SGPT) mean was 60.13 in mothers with complications compared to 23.87 in uncomplicated mothers (p=0.001). Lactate dehydrogenase (LDH) mean was 2235.38 in mothers with complications and 735.02 in mothers without complications. In patients with fetal complications LDH levels were 385.35 and in cases without fetal complications 375.02.
Conclusion: The level of liver enzymes and the presence of antiphospholipid syndrome are considered as predictors of maternal complications, while lactate dehydrogenase and signaling in the mother predict maternal and fetal complications.
Article Type: Case Report |
Subject:
Reproduction
Received: 2018/06/7 | Accepted: 2019/03/16 | Published: 2019/06/15
Received: 2018/06/7 | Accepted: 2019/03/16 | Published: 2019/06/15
English Expanded Abstract [HTML 19 KB] (105 Download)
References
1. Maternal mortality. World Health Organization; 2016. [Link]
2. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: A WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33. [Link] [DOI:10.1016/S2214-109X(14)70227-X]
3. Osungbade KO, Ige OK. Public health perspectives of preeclampsia in developing countries: Implication for health system strengthening. J Pregnancy. 2011;2011. [Link]
4. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-7. [Link] [DOI:10.1053/j.semperi.2009.02.010] [PMID]
5. Dolea C, AbouZahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. World Health Organization:Geneva;2003. [Link]
6. Kharaghani R, Esfahani BO, Cheraghi Z, Mohammadian Z, Nooreldinc RS. Prevalence of preeclampsia and eclampsia in Iran. Arch Iran Med. 2016;19(1):64-71. [Link] [PMID]
7. Roberts JM, Gammill HS. Preeclampsia. Hypertension. 2005;46(6):1243-9. [Link] [DOI:10.1161/01.HYP.0000188408.49896.c5] [PMID]
8. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44. [Link] [DOI:10.1016/S0140-6736(10)60279-6]
9. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;8:7-12. [Link] [PMID] [PMCID]
10. Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71(suppl_1):S18-25. [Link]
11. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet.Gynecol. 2013;209(6):544.e1-12. [Link] [DOI:10.1016/j.ajog.2013.08.019] [PMID]
12. Paré E, Parry S, McElrath TF, Pucci D, Newton A, Lim KH. Clinical risk factors for preeclampsia in the 21st century. Obstet Gynecol. 2014;124(4):763-70. [Link] [DOI:10.1097/AOG.0000000000000451] [PMID]
13. Wikström AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk. Hypertension. 2010;55(5):1254-9. [Link] [DOI:10.1161/HYPERTENSIONAHA.109.147082] [PMID]
14. Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low-and middle-income countries: a WHO secondary analysis. PloS one. 2014;9(3):e91198. [Link] [DOI:10.1371/journal.pone.0091198] [PMID] [PMCID]
15. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753. [Link] [DOI:10.1136/bmj.i1753] [PMID] [PMCID]
16. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Pre‐eclampsia, eclampsia and adverse maternal and perinatal outcomes: A secondary analysis of the world health organization multicountry survey on maternal and newborn health. BJOG: An International Journal of Obstetrics & Gynaecology. 2014;121(s1):14-24. [Link] [DOI:10.1111/1471-0528.12629] [PMID]
17. Stevens W, Shih T, Incerti D, Ton TG, Lee HC, Peneva D, et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017;217(3):237-48. [Link] [DOI:10.1016/j.ajog.2017.04.032] [PMID]
18. Gibbs RS, Karlyn BY, Haney AF, Nygaard I. Danforth's obstetrics and gynecology. 10th Edition. Philadelphia: Wolters Kluwer Health Adis (ESP); 2012. [Link]
19. Harmon QE, Huang L, Umbach DM, Klungsøyr K, Engel SM, Magnus P, et al. Risk of fetal death with preeclampsia. Obstet Gynecol. 2015;125(3):628-35. [Link] [DOI:10.1097/AOG.0000000000000696] [PMID] [PMCID]
20. Saadat M, Nejad SM, Habibi G, Sheikhvatan M. Maternal and neonatal outcomes in women with preeclampsia. Taiwan J Obstet Gynecol. 2007;46(3):255-9. [Link] [DOI:10.1016/S1028-4559(08)60029-7]
21. Aali BS, Ghafoorian J, Mohamad-Alizadeh S. Severe preeclampsia and eclampsia in Kerman, Iran: Complications and outcomes. Med Sci Monit. 2004;10(4):CR163-7. [Link] [PMID]
22. Priso EB, Njamen TN, Tchente CN, Kana AJ, Landry T, Tchawa UF, et al. Trend in admissions, clinical features and outcome of preeclampsia and eclampsia as seen from the intensive care unit of the Douala General Hospital, Cameroon. Pan Afr Med J. 2015;21(1):103-7. [Link] [DOI:10.11604/pamj.2015.21.103.7061]
23. von Dadelszen P, Payne B, Li J, Ansermino JM, Pipkin FB, Côté AM, et al. Prediction of adverse maternal outcomes in pre-eclampsia: Development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27. [Link] [DOI:10.1016/S0140-6736(10)61351-7]
24. Kozic JR, Benton SJ, Hutcheon JA, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004. [Link] [DOI:10.1016/S1701-2163(16)35048-4]
25. Umasatyasri Y, Van I, Shamita P. Role of LDH (Lactate dehydrogenase) in preeclampsia eclampsia as a prognostic marker: An observational study. Int Arch Integr Med. 2015;2(9):88-93. [Link]
26. Thangaratinam S, Koopmans CM, Iyengar S, Zamora J, Ismail KM, Mol BW, et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with preeclampsia: A systematic review. Acta Obstet Gynecol Scand. 2011;90(6):574-85. [Link] [DOI:10.1111/j.1600-0412.2011.01112.x] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
